E
Eric Pautas
Researcher at University of Paris
Publications - 89
Citations - 1752
Eric Pautas is an academic researcher from University of Paris. The author has contributed to research in topics: Warfarin & Population. The author has an hindex of 20, co-authored 83 publications receiving 1622 citations. Previous affiliations of Eric Pautas include Paris Descartes University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Human NK cells display major phenotypic and functional changes over the life span.
Magali Le Garff-Tavernier,Magali Le Garff-Tavernier,Vivien Béziat,Vivien Béziat,Julie Decocq,Julie Decocq,Virginie Siguret,Frédérique Gandjbakhch,Eric Pautas,Patrice Debré,Patrice Debré,Hélène Merle-Béral,Hélène Merle-Béral,Vincent Vieillard,Vincent Vieillard +14 more
TL;DR: It is concluded that the preservation of NK cell features until very advanced age may contribute to longevity and successful aging.
Journal ArticleDOI
Elderly Patients Treated with Tinzaparin (Innohep ® ) Administered once Daily (175 Anti-Xa IU/kg): Anti-Xa and Anti-IIa Activities over 10 Days
Virginie Siguret,Eric Pautas,M. Février,C. Wipff,B. Durand-Gasselin,M. Laurent,J.-P. Andreux,M. d’Urso,Pascale Gaussem +8 more
TL;DR: Tinzaparin may be administered safely at a treatment dose (175 anti-Xa IU/kg) in older patients with age-related renal impairment and neither dose adjustment, nor serial anti- Xa activity monitoring seems to be required in patients with creatinine clearance above 20 mL/min during the first ten day treatment.
Journal ArticleDOI
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.
Eric Pautas,Eric Pautas,Caroline Moreau,Isabelle Gouin-Thibault,Isabelle Gouin-Thibault,Jean Louis Golmard,Isabelle Mahé,C. Legendre,E. Taillandier-Heriche,B. Durand-Gasselin,Anne-Marie Houllier,P. Verrier,P Beaune,P Beaune,Marie-Anne Loriot,Marie-Anne Loriot,Virginie Siguret,Virginie Siguret +17 more
TL;DR: In this special population of frail elderly patients with multiple comorbidities and polypharmacy, the main impact of genetic factors on warfarin response is demonstrated.
Journal ArticleDOI
Risk Factors for Deep Vein Thrombosis in Inpatients Aged 65 and Older: A Case‐Control Multicenter Study
Sébastien Weill-Engerer,Sylvie Meaume,Amina Lahlou,François Piette,Olivier Saint-Jean,Annick Sachet,Jean-Yves Beinis,Claude Gallinari,Anne-Sophie Grancher,Jean-Pierre Vincent,Henri Naga,Joël Belmin,Rosella Salvatore,Marie Kazes,Eric Pautas,André Boiffin,Jean-Bernard Piera,Monique Duviquet,David Knafo,Andrée Piau,Dragoslav Miric,Alain Jean,Valérie Bellamy,Olivier Tissandier,Alain-Ferdinand Le Blanche +24 more
TL;DR: To identify independent risk factors of symptomatic deep vein thrombosis (DVT) in geriatric inpatients and to define high‐risk patients likely to benefit from preventive treatment.
Journal ArticleDOI
Initiation of warfarin therapy in elderly medical inpatients: A safe and accurate regimen
Virginie Siguret,Isabelle Gouin,Matthieu Debray,Christine Perret-Guillaume,Jacques Boddaert,Isabelle Mahé,Valérie Donval,Marie-Laure Seux,Marjolaine Romain-Pilotaz,Mathilde Gisselbrecht,Marc Verny,Eric Pautas +11 more
TL;DR: A simple low-dose regimen for starting warfarin therapy in elderly inpatients was developed, which was simple, safe, and accurate in predicting the daily maintenance warFarin dose in elderly hospitalized patients.